Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

ROCKY MOUNTAIN TOX, LLC

NPI: 1710966460 · AURORA, CO 80011 · Clinical Medical Laboratory · NPI assigned 01/11/2006

$236K
Total Medicaid Paid
17,599
Total Claims
4,453
Beneficiaries
5
Codes Billed
2018-01
First Month
2020-05
Last Month

Provider Details

Authorized OfficialFREEMAN, SYLVIA (MGR OF CREDENTIALING/ENROLLMENT)
NPI Enumeration Date01/11/2006

Related Entities

Other providers sharing the same authorized official: FREEMAN, SYLVIA

ProviderCityStateTotal Paid
REGIONAL TOXICOLOGY SERVICES, LLC TACOMA WA $60.35M
AMERICAN FORENSIC TOXICOLOGY SERVICES LLC HUNTINGTON NY $33.21M
SECON OF NEW ENGLAND LLC WORCESTER MA $8.88M
TECHNICAL RESOURCE MANAGEMENT LLC INDIANAPOLIS IN $119.72

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 7,657 $114K
2019 9,405 $117K
2020 537 $6K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 13,054 3,260 $198K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 909 306 $18K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 121 117 $15K
80348 883 302 $4K
82945 2,632 468 $2K